Introduction
Stem cell failure may be primary or secondary due to systemic diseases or iatrogenic causes. Bone marrow failure syndromes are very illustrative with regard to the pathophysiology of the stem-cell compartment, its physiologic and pathophysiologic regulation as well as mechanisms of clonal evolution and persistence. Although aplastic anemia (AA) is the prototype of primary hematopoietic stem cell failure, 1,2 depletion or functional deficiency of stem cells also occurs in myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). In most cases of idiopathic AA, depletion of the stem cell compartment is due to autoimmune attack by T lymphocytes and damage exerted by inhibitory cytokines, products of activated immune cells. Such autoimmune pathophysiology seems to promote expansion of a PNH clone characterized by a mutant PIG-A gene, while in some patients PNH develops without obvious phase of aplasia. 3, 4 Similar to other somatic defects, this mutation constitutes a marker of clonal hematopoiesis. Typically, clonal chromosomal aberrations are not present in typical AA and PNH. Evolution of clonal hematopoiesis indicated by the occurrence of chromosomal defects is a well-known complication of AA, observed in the setting of refractory disease and or recurrent cytopenias. 5 MDS that develops in the context of AA is often associated with deletions involving chromosome 7 and trisomy-8 ( Table 1) .
Typical MDS develops without a period of aplasia and is characterized by clonal hematopoiesis, cytopenias and frequent progression to acute myeloid leukemia (AML). Similar to AA and PNH, the normal stem cell compartment is severely contracted. 6, 7 A typical feature of MDS is the presence of invariant chromosomal abnormalities, which with some exceptions (chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukaemia (aCML); Table 2 ) are mostly unbalanced. The clonal chromosomal defects affect certain chromosomes more frequently. The resulting loss of heterozygosity (LOH) or duplications may involve genes related to malignant transformation. Conversely, it is likely that defects involving some of the chromosomes are lethal to the cells, explaining the spectrum of defects encountered (Table 2) .
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Hematopoiesis may be clonal in AA, likely due to contraction of the stem cell pool. Evolution of a dominant hematopoietic clone is most obvious in PNH as it can be easily recognized by the presence of a characteristic phenotype. 3, 5, 8, 9 In contrast to the benign nature of clonality in AA and PNH, MDS appears to result from malignant or pre-malignant transformation. In cases with normal cytogenetics, clonality in MDS can be detected by X-chromosome inactivation patterns while chromosomal defects can serve as suitable clonality markers in patients with an abnormal karyotype. 10, 11 A quantitative defect of stem cells has been documented in AA, PNH and MDS as measured by flow cytometry of CD34 þ cells, colony-forming cells as well as long-term culture initiating cells, the most immature in vitro equivalents of hematopoietic stem cells. 3, [12] [13] [14] [15] Such a depletion of normal stem cells may be a result of an immune attack and is frequently found not only in AA but also in MDS, as evidenced by a significant response rate to immunosuppressive therapies seen in patients with MDS. [16] [17] [18] Similarly, a significant minority of patients with MDS presents with a hypocellular bone marrow. Immune-mediated bone marrow failure is the predisposing factor for the evolution of PNH rather than simple stem cell depletion as PIG-A gene-deficient clones cannot be found in iatrogenic forms of bone marrow aplasia. PNH clones are present in a majority of patients with AA and also, albeit rarely, in MDS, 1 consistent with the strong immune component of the pathogenesis of this disease. Overt PNH frequently develops as a late complication of AA. In both primary PNH as well as PNH evolving secondary to AA, severe depletion of normal stem cells is present. 19, 20 One of the possible pathophysiologic mechanisms that may help explain contraction of the stem cell pool is thought to involve stem cell telomeres. For example, dysfunction of the telomere machinery, as observed in congenital forms of AA such as dyskeratosis congenita, [21] [22] [23] may be the primary cause of contraction of the stem cell pool. Similarly, progressive loss of telometric repeats during aging may be one of the factors responsible for decreasing bone marrow cellularity, decreased numbers of stem and progenitor cells and increased propensity to develop MDS. Conversely, depletion of the early compartment and overt stress to the residual stem cells may lead to telomere shortening. 24, 25 Clonality in the context of contraction of the stem cell compartment
Clonal expansion versus stem cell depletion Mechanisms of clonal evolution. Several theories can be put forward to explain the initial steps in the evolution of clonal stem cell diseases such as MDS (Figure 1) . Contraction of the stem cell compartment may result in a 'benign clonality' of hematopoiesis. For example, in AA blood cells may be clonal or oligoclonal as a result of very few stem cells contributing to blood production; polyclonal hematopoiesis is restored upon successful therapy. Observation of the disappearance of clonal abnormalities following successful immunosuppressive therapy and restoration of polyclonal hematopoiesis also supports the notion that clonal outgrowth may be a result of decreased numbers of operative normal hematopoietic clones.
In contrast, acquisition of a genetic defect by an individual stem cell resulting in clonal expansion may be the primary event leading to the gradual dis-replacement of normal hematopoiesis. If chromosomal defects arise after stem cell recruitment, the early progenitors rather than true stem cells are subject to chromosomal damage and act as a source of clonal expansion ( Figure 2) . However, such a scenario leaves the question open as to the mechanisms of cytopenia early in the disease, which would be difficult to explain simply by mechanical displacement of normal hematopoiesis. Of note is that while telomeric erosion may accompany the persistence of a singular clone, by itself telomere shortening is not a limiting factor for the long-term function of the defective stem cell. In MDS, clonal evolution has a malignant character and is associated with the stepwise acquisition of a more aggressive phenotype, likely due to secondary defects acquired in the process of gradual clonal and subclonal selection. Additional defects may convey a growth advantage, facilitate immune escape and apoptosis resistance. This process may explain why AML slowly evolving in the context of MDS is refractory to current therapies. Apart from chromosomal aberrations, clonal transformation may be associated with occurrence of mutations in oncogenes or tumor suppressor genes including, for example, RAS, bcl-2 and p53. [26] [27] [28] [29] It is also possible that activation of telomerase activity may be a part of this process, preventing simple exhaustion of the malignant stem cell. In PNH, clonality is a result of the outgrowth of a single hematopoietic clone that can persist for many years. 30 Interestingly, the presence of a low frequency of PNH cells even in healthy individuals is consistent with the theory that defective stem cells actually predate the stem cell failure and depletion. 31 Unlike dysplastic clones in MDS, which harbor intrinsic defect(s) predisposing to clonal evolution, in PNH external factors such as pressure exerted by the immune system may be required for clonal escape. 
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According to an alternative theory, defective stem cells may exist in a quiescent form; such abnormal stem cells carrying a genetic defect may be more likely recruited for proliferation and initiate clonal evolution in the context of an overall depletion of the stem cell pool ( Figure 1 ). Thus, the frequent detection of distinct clonal abnormalities in MDS may be an epiphenomenon and a mere sign of a contracted stem cell pool. As a consequence of this theory, abnormal stem cells would be more frequent in patients who are prone to develop MDS as their chances for recruitment would be much higher. An increased prevalence of MDS in the elderly population is consistent with the accumulation of abnormal stem cells or deletion/exhaustion of normal stem cells. An underlying deficiency of stem cells may also be responsible for failure to restore hematopoiesis following myelotoxic therapy of highgrade MDS and secondary AML.
The frequent evolution of clonal defects in AA supports the theory that a general contraction of the stem cell pool may lead to the more frequent recruitment of an abnormal hematopoietic clone without dilution by normal cells. The best evidence for the preexistence of many defective stem or progenitor cells could be provided if cytogenetic analysis is individually performed on purified precursors at the time when hematopoiesis is still polyclonal. However, due to the nature of currently applied cytogenetic methods, detection of such defects is possible only if an abnormal clone becomes dominant and a critical number of defective progenitor cells are reached.
Stem cell versus progenitor clonality
The question as to which level of hematopoietic ontogenesis is initially affected by the clonal chromosomal defect has been investigated in MDS and PNH. In MDS, the results of these studies differ depending on the type of lesion studied (Figure 2 ). For example, deletion of 5q has been detected in the most phenotypically immature hematopoietic cells, 32 while trisomy-8 appears to evolve at later stages of hematopoietic maturation. 33 Some authors concluded that the initial trisomy-8 lesion occurs at the level of CFU-GEMM as lymphoid cells (both T-and B-cells) were not derived from the pathogenic clone. 34 In patients with concomitant PNH and MDS, trisomy-8 was found in the portion of glycosylphosphatidylinositol-deficient cells indicating that the PIG-A mutation affected the stem cell first and chromosomal aberration evolved as a subclone later. 35 In MDS with deletion 20q abnormality, EBV lymphoblastoid cell lines with and without the abnormality were successfully generated, suggesting that the common precursor for myeloid and B lymphocytes is affected. 36 Leukemias with trilineage dysplasia are frequently CD34 þ and contain major chromosomal abnormalities, again suggesting a transformation step at the level of more immature CD34 þ cells. 37 
Mature blood cell production in clonal hematopoiesis
In clonal bone marrow failure syndromes, mature cells may be derived from the dominant 'defective' clone or from residual A stem cell may gain a lesion that, in the appropriate environment, leads to clonal expansion due to positive selection. Alternatively, the lesion may not be intrinsically permissive; under conditions of stem cell depletion, defective stem cells are more likely to be recruited initiating clonal evolution. 'Benign clonality' be a result of severe deficiency of stem cells whereas only one or few stem cell are providing supply of mature cells at any given time. In such a case, clonal DNA markers indicating abnormality are not present. normal cells. While in PNH the mature progeny cells are affected by the mutation, that is defective stem cells normally contribute to blood production, in MDS mature cells are not consistently derived from the aberrant clone. For example, the derivation of the residual mature cells (either from abnormal or from residual normal stem cells) may depend upon the type of lesion. Dysmorphic changes in mature leukocytes could imply that they are derived from the defective MDS clone but could also be consistent with a dysfunction of the residual non-clonal stem cells. In fact, in one study, 6-43% hypogranulated and 33-40% pelgeroid granulocytes derived from patients with monosomy-7 and trisomy-8 were found to carry the abnormal chromosomes. 38 In some studies (for example, trisomy-8), all granulocytes were abnormal by fluorescence in situ hybridization (FISH), but in others, normal and abnormal granulocytes coexisted. 33, 34, 39 Similar findings were also reported for monosomy-7 and deletion Y. 40, 41 Treatment with 5-azacytidine resulted in the elimination of the abnormal clone from the granulocytic population as measured by interphase FISH. 42 It is possible that, unlike in AML where all mature cells can only reflect residual normal hematopoiesis, in MDS the aberrant clone is capable of the production/function of mature progeny so that differentiated progeny may correspond to a mixture of both clonal and normal cells. 39, 40, 43 However, the ability to produce differentiated progeny may depend on the type of the genetic lesion that in certain circumstances may result in a total maturation block. Of note is that lack of a clonal marker in all or some of the mature cells may not exclude clonality. Conversely, a pathogenic chromosomal abnormality may just be a secondary lesion affecting only a subclonal population.
Mechanisms leading to unbalanced chromosomal lesions
If chromosomal aberrations are random and occur at a steady frequency, their evolution during aging may be facilitated by depletion of the stem cell pool and oligoclonal hematopoiesis. However, it is also likely that the general propensity for the development of chromosomal breaks may be a result of DNA repair defects or lesions within the mitotic spindle mechanism. Similarly, dysfunction of telomeres including excessive shortening, dysfunction of telomere protein caps, defects in the 3 0 overhang or various lesions within the telomerase complex 44, 45 could lead to illegitimate chromosome end-to-end fusion and breakage-fusion-bridge cycles, ultimately resulting in translocation, deletion and amplification. In addition to proteins of telomerase complex, POT1 appears not only to be involved in the regulation of telomere length and telomerase function 46, 47 but also may inhibit action of the double-stranded break machinery at the chromosomal ends. 48 Consequently, protein caps may prevent chromosomal fusions that could result from homologous end-joining or recombination resulting in sister chromatid exchanges and formation of telomere circles. [48] [49] [50] AML patients with multiple chromosomal aberrations and some patients with MDS show excessively shortened telomeres 51, 52 without low telomerase activity or decreased expression of capping proteins such as TRF1 or POT1; in contrast, a compensatory high telomerase activity and expression of TRF2 in MDS has also been reported. 51 High telomerase activity appears to correlate with progression of MDS to AML. 53 In contrast, mutations in the human telomerase RNA gene does not appear to be frequent in MDS.
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Mature blood cells derived from abnormal clone Figure 2 Timing of clonal defect. If a clonal defect arises in a stem cell, all three lineages derived from that stem cell will carry the lesion. Most of the lesions do not involve lymphohematopoietic stem cells as lymphocytes are usually polyclonal. In some instances, progenitors rather than stem cells are the initial source of clonal evolution. Both stem cell and progenitor-derived clones can variably contribute to mature progeny production.
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Regardless of which mechanism is operative, loss of whole chromosomes or chromosomal segments may result in various attempts of the cell to correct the lesion; if the homologous chromosome is used as a template for mitotic recombination uniparental disomy (UPD) may be the end product. 55 However, if a heterologous chromosome is utilized as a template for the repair of the segmental losses, chromosomal translocation may be the result (Figure 3 ).
Clinical consequences of clonal aberrations
Clonal evolution and chromosomal abnormalities
Following genomic injury, the chromosomal defects may determine the phenotype and behavior of the disease. In MDS, clonal abnormalities as detected by metaphase cytogenetics have important prognostic and more recently, therapeutic implications. [56] [57] [58] [59] Additional abnormalities may negatively affect the general prognosis of each specific lesion as demonstrated, for example, by the analysis of outcomes when additional defects are found in patients with deletion 5q and other abnormalities. 60 Clearly, complex karyotypes showed the worst prognosis, suggesting that the acquisition of a malignant phenotype is a result of or accompanies the progressive addition of new chromosomal breaks. It is also possible that certain defects constitute the 'initiating lesion' and predispose to subsequent lesions, which modify the initial phenotype and usually result in a clinically more aggressive phenotype. Such a 'primacy' of the 5q defect has been described in conjunction with trisomy-8. This defect appears to evolve at the level of more mature progenitors, which are derived from a stem cell carrying a deletion 5q. 33 The specificity of Revlimid for clones carrying deletion 5q is very instructive in terms of the biology of this chromosomal lesion. 58, 59 Regardless of the mechanisms of action, Lenalidomide (Revlimid) also showed remarkable effects in patients in whom additional lesions were present, suggesting that the del5q was the primary pathogenic chromosomal lesion. 61 Other possible 'founder' lesions may exist, such as monosomy-7. It is possible that the primary lesion is acquired at the level of the hematopoietic stem cell while additional, secondary defects occur in progenitor cells.
Functional consequences of unbalanced lesions
In addition to their prognostic significance, chromosomal aberrations can serve as a clonality marker and may point towards genes responsible for the clonal transformation and phenotype. It is likely that individual defects translate into specific phenotypes and result in specific clinical outcomes. Owing to deletion, LOH may lead to haploinsufficiency or hemizygosity for minor gene variants that are normally silent in the heterozygous form. Alternatively, somatic mutations may become 'exposed' and functionally meaningful through the loss of the remaining wild type allele. In a similar way, UPD may have similar consequences, but will result in homozygosity for the minor alleles or polymorphisms present in the germ-line or duplication of somatically acquired mutations. The functional consequences of the duplication of chromosomes or chromosome segments are more complex and may translate into gene-dose effects or amplification of negative functional consequences of acquired mutations.
Methods of detection of clonal chromosomal defects
Limitations of current karyotyping technologies
While karyotypic abnormalities, if present, are suitable markers of clonality (also see below), approximately 50% of patients with MDS display no chromosomal defects using routinely applied tests 56, 57, [62] [63] [64] (Table 2 ). AA is characterized by a normal karyotype and lack of clonal chromosomal markers but some investigators believe that the presence of a chromosomal defect is not inconsistent with the diagnosis of AA. That cytogenetic lesions are not detected in all patients with MDS and are absent perhaps in a higher proportion of patients with AA may due to either to the resolution level of routine metaphase cytogenetics (lesion size) or to low sensitivity allowing for detection of only large clones (proportion of clonal cells). The presence of smaller lesions could help explain the variability in the clinical phenotype and treatment responses in patients with a seemingly obvious chromosomal profile like 5q syndrome or deletion 20q.
Another possible limitation of the diagnostic readout of metaphase karyotyping is its restriction to dividing cells, resulting in an overestimation of the contribution of the aberrant clone to the whole hematopoietic output; normal progenitors may be inhibited and mature non-dividing cells may be derived from the normal clones. Conversely, if proliferation of dysplastic cells is difficult to induce, the chromosomal defect may remain undetected. In such a case, single nucleotide polymorphism arrays (SNP-arrays) and interphase fluorescent in situ hybridization (FISH) 65 may help identify a clonal marker. 66 In an attempt to improve the sensitivity of cytogenetic analysis, various techniques including FISH were employed (Table 3 ). In FISH, specific fluorescently labeled probes are hybridised to the nuclei of interphase cells attached to glass slides. FISH does not require cell division and consequently cell culture and is more sensitive than traditional cytogenetics, providing a more accurate measure of the true frequency of abnormal cells and detection of smaller sized clones. 62, 67, 68 Depending on the number of cells scored in patients or controls, 41 or 2% of cells with an abnormal karyotype may be pathologically significant. 69 Owing to the false-positive rate, it is not clear whether the sensitivity can be increased through routine counting of a higher number of cells. However, FISH studies suggest that the large proportion of MDS with seemingly normal karyotypes may be due to the relative insensitivity of metaphase cytogenetics; the defects can be detected only if 410% of metaphases are consistently abnormal. Of note is that FISH is more reliable for the detection of duplications rather than deletions of chromosome fragments. Unlike array-based Clonality of the stem cell compartment R Tiu et al technologies (see below), FISH probes can be designed to detect both unbalanced and balanced chromosomal lesions for which dual color/dual fusion, single fusion/dual color or two-color break-apart FISH probes have been developed. However, the major drawback of the clinical application of FISH is that it utilizes a limited number of probes directed towards already known or suspected targets and thus new defects located in other chromosomal regions cannot be detected. When the clonal defect is known, targeted application of this technology is possible and is probably more useful as a confirmatory test.
New karyotyping technologies
On account of the low resolution of metaphase karyotyping, new techniques, based on DNA array technologies, have been developed allowing for detection of smaller lesions. These new methods include SNP arrays (SNP-A) or oligonucleotide arraybased comparative genomic hybridization (CGH-A). Both technologies allow for a very precise genomic scan and do not require cell division. Additionally, the level of resolution is theoretically limited only by the number of probes used for the generation of the arrays and is much greater than that of routine metaphase cytogenetics. 66, [70] [71] [72] [73] In CGH-A, competitive hybridization of differentially labeled reference and sample DNA is used to determine copy number differences based on the spectral changes of individual probes, which occur following hybridization to oligonucleotide array. Such an array contains a large number of oligo-DNA probes distributed throughout the genome. As CGH-A does not rely on the presence of SNPs, the probes can be very evenly and densely distributed, allowing for a better resolution than SNP-A karyotyping (see below) and great deal of reliability as many probes can be designed to cover each individual gene (Table 3) .
In SNP-A karyotyping, genomic DNA is fragmented, amplified, labeled and hybridized to high-density arrays containing probes corresponding to individual alleles thereby allowing for the distinction of polymorphic gene variants (Figure 4 ). SNP Figure 4 Principle of SNP-A karyotyping. High-density DNA arrays contain DNA probes to allelic variants of SNPs. DNA to be examined is digested, ligated to universal linkers, amplified and hybridized to the DNA chips. The right lower portion of the figure depicts the final data output for an exemplary chromosome. In the case illustrated here, there is a segmental deletion within chromosome 12. Red and blue dotted tracings correspond to the individual hybridization signals of probes positioned along chromosome 12. The resultant line oscillates around diploid copy number line except at the position where hybridization signals are weaker due to hypoploidy of the corresponding regions. In addition to gene copy number determination, SNP arrays allow for discrimination of hetero-versus homozygosity for individual SNPs: small green bars correspond to the heterozygosity calls. In the deleted area, the density of these calls is much lower due to LOH. The residual heterozygosity calls in this region are reflection of contamination with non-clonal cells contained in the tested sample.
Clonality of the stem cell compartment R Tiu et al probes are also distributed throughout the genome, but the coverage less even because they are limited to the location of individual polymorphisms. Figure 5 Level of sensitivity for detection of clonal lesions. All cytogenetic detection strategies have an inherent threshold of detection. For clones to be detected they must contribute to the cell pool at a level greater than the detection threshold. If multiple lesions are identified using SNP arrays it is not possible to determine whether this is due to multiple discrete clones harboring individual lesions, or a compound lesions in a single clone. Due to the relative insensitivity of SNP karyotyping only large clones can be detected making detection of lesions from multiple clones rather than complex karyotypes of a singular clone unlikely. Metaphase karyotyping does not have this inherent problem and allows for a better distinction of compound defects from defects present in multiple clones. Figure 6 SNP array versus metaphase cytogenetics. The advantages and disadvantages of metaphase karyotyping as compared to high-density SNP array-based karyotyping are illustrated.
Metaphase karyotyping SNP array karyotyping
Clonality of the stem cell compartment R Tiu et al variety of malignancies and germ-line defects. 71, [74] [75] [76] [77] [78] [79] [80] [81] In addition to copy number estimation, SNP-A allows for precise determination of LOH, even without loss of ploidy (UPD). 45, 55, 82, 83 Of note is that SNP-A reflects the contribution of the clone to the total cell population present in the test sample. In contrast, metaphase karyotyping only measures the proportion of dividing cells that is abnormal and does not allow for the determination of the clonality of the mature post-mitotic cells. If many clones (all characterized by diverse defects) are present, their overall frequency would be low and they would not be detected ( Figure 5 ). It is possible that such a clonal diversity exists and theoretically could be detected if limiting dilution techniques of early precursors were applied.
SNP-A can be very helpful in identifying clonal chromosomal aberrations in MDS. We have systematically applied 50K and 250K SNP-A karyotyping to study LOH and copy number changes in patients with bone marrow failure disorders, including AA and MDS. We were able to identify previously cryptic lesions in patients with normal or uninformative cytogenetics by routine analysis ( . Interestingly, such lesions were often located on chromosomes that are not commonly affected by unbalanced aberrations. In addition, we found UPD as a sole or compound abnormality in around 30% of MDS cases. These findings are consistent with the theory that metaphase cytogenetics underestimates the prevalence of chromosomal defects in MDS. Moreover, a systematic genome scan using, for example, SNP arrays may allow for the identification of new invariant lesions associated with specific clinical phenotypes. Clinically, SNP-A may complement routine cytogenetics ( Figure 6 ). The relative insensitivity of this method with regard to the minimal size of the clone detected may provide an advantage as only major, likely clinically relevant clones are detected. In our experience at least 70% of cells have to carry a lesion to be detected. However, inherent to the nature of SNP array technology, the results do not provide any information as to whether the detected lesions are all present in a single clone or exist in several codominant clones ( Figure 6 ). In the future, the increased precision of SNP-A, its reliability and potential for automation may complement the spectrum of existing cytogenetic techniques allowing for better diagnosis and prognostication.
